A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)
This study has been completed.
Information provided by:
First received: September 23, 2004
Last updated: May 24, 2013
Last verified: May 2013
The purpose of this study is to evaluate the lipid lowering effects of an investigational drug in patients with hypercholesterolemia (high cholesterol).
Drug: MK0653A, ezetimibe (+) simvastatin
Drug: Comparators: simvastatin and ezetimibe
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Multicenter, Randomized, Double-Blind, Placebo-Controlled, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Merck:
Primary Outcome Measures:
- Plasma LDL-C
Secondary Outcome Measures:
- Plasma LDL-C, TG and HDL-C. The proportion of patients achieving LDL-C targets. Tolerability.
|Study Start Date:||September 2002|
|Primary Completion Date:||June 2003 (Final data collection date for primary outcome measure)|
The duration of treatment is 4 months.
Contacts and Locations